CD274 and early-onset autosomal dominant Alzheimer disease: This approach is currently being studied in an ongoing Phase 1 clinical trial (NCT05551741) in persons with Alzheimer’s disease for intravenous IBC-Ab002, a novel fully human anti-PD-L1 antibody [13].